Cosmax BTI, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cosmax BTI, Inc. - overview
Established
1992
Location
Seongnam, Gyeonggi, South Korea
Primary Industry
Consumer Products
About
Cosmax BTI, Inc. is a South Korean biotechnology firm specializing in innovative biopharmaceutical solutions and advanced drug delivery systems aimed at enhancing healthcare outcomes. Founded in 1992 in Seongnam, South Korea, Cosmax BTI, Inc. focuses on developing biopharmaceutical products.
The company has raised a total of KRW 83. 8 billion through various funding rounds, with the latest PIPE round in February 2002 raising KRW 5. 1 billion from UBS AM - REPM. Cosmax BTI has completed 2 deals since inception, cementing its presence in the biotechnology sector and expanding its operations globally.
Cosmax BTI specializes in delivering solutions tailored for the biotechnology and pharmaceutical sectors. Its core offerings include a range of biopharmaceuticals and advanced drug delivery systems that enhance therapeutic efficacy and patient outcomes. The company serves pharmaceutical companies, healthcare providers, and research institutions across North America, Europe, and Asia, focusing on solutions that address challenges in drug bioavailability and targeted therapies. In 2024, Cosmax BTI reported a revenue of KRW 1,589,211,436.
6, with an EBITDA of KRW 140,018,569. 3. The company generates revenue through direct sales and strategic partnerships, collaborating with pharmaceutical firms to provide tailored biopharmaceutical products and offering subscription-based services to enhance customer engagement. Cosmax BTI plans to further develop its product line, focusing on new biopharmaceuticals and drug delivery systems, with potential launches in the upcoming years.
The company aims to expand into additional markets in North America and Europe by 2025. Recent funding will support these initiatives, continuing the company's trajectory since its last deal in February 2002, which raised KRW 3. 5 billion during an IPO.
Current Investors
UBS Asset Management - Real Estate and Private Markets
Primary Industry
Consumer Products
Sub Industries
Beauty & Hygiene
Website
www.cosmaxbti.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Cosmax BTI, Inc. - timeline of key events
Cosmax BTI, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 336,230,290,992 | 533,342,717,781 | 756,963,564,655 | 883,950,013,573 | 1,259,716,816,059 | 1,330,652,928,971 | 1,382,880,688,515 | 1,591,487,621,503 | 1,600,125,770,194 | - | - | - |
| % Revenue Growth (YoY) | - | 58.6% | 41.9% | 16.8% | 42.5% | 5.6% | 3.9% | 15.1% | 0.5% | - | - | - |
| EBITDA (USD) | 30,920,529,163 | 45,059,324,777 | 65,161,009,485 | 55,374,744,103 | 77,621,878,509 | 91,988,156,641 | 112,461,495,317 | 174,401,515,215 | 111,909,450,398 | - | - | - |
| Operating Income (USD) | 24,338,237,195 | 35,934,351,724 | 52,615,998,585 | 35,140,124,481 | 52,337,973,702 | 53,995,136,812 | 66,641,426,851 | 122,599,910,142 | 53,100,853,848 | - | - | - |
| Operating Margin | 7.2% | 6.7% | 7.0% | 4.0% | 4.2% | 4.1% | 4.8% | 7.7% | 3.3% | - | - | - |
| % EBITDA Margin | 9.2% | 8.4% | 8.6% | 6.3% | 6.2% | 6.9% | 8.1% | 11.0% | 7.0% | - | - | - |
| NET Income (USD) | 15,756,824,739 | 18,885,577,415 | 31,440,053,248 | 15,520,150,514 | 21,062,588,320 | 18,319,679,109 | (29,053,381,423) | 34,336,481,889 | (16,446,826,860) | - | - | - |
| % Net Margin | 4.7% | 3.5% | 4.2% | 1.8% | 1.7% | 1.4% | (2.1%) | 2.2% | (1.0%) | - | - | - |
Cosmax BTI, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Cosmax BTI, Inc. | - | ||||||||
| IPO | Completed | Cosmax BTI, Inc. | - |
Displaying 1 - 2 of 2
Cosmax BTI, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.